Breaking News Instant updates and real-time market news.

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

19:35
09/22/19
09/22
19:35
09/22/19
19:35

Fly Intel: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. A block of WeWork directors is planning to push Adam Neumann to step down as CEO after a tumultuous week in which his eccentric behavior and drug use came to light and the startup delayed its much-anticipated stock-market listing, The Wall Street Journal's Maureen Farrell, Liz Hoffman, Eliot Brown and David Benoit reported. Meanwhile, Reuters' Anirban Sen and Joshua Franklin also wrote that SoftBank (SFTBY), the biggest investor in WeWork owner We Company (WE), is exploring ways to replace Adam Neumann as CEO of the office-sharing start-up. This comes after We Company postponed its initial public offering last week, following pushback from perspective investors, not just over its widening losses, but also over Neumann's unusually firm grip on the company, the authors noted. 2. Deutsche Bank (DB) is close to completing a deal with BNP Paribas (BNPQY) to transfer its prime brokerage business to the French bank, Reuters' Donal Griffin and Steven Arons reported, citing people familiar with the matter. The transaction may be announced as early as Monday, sources said. 3. Opioid lawsuits have already hammered the share prices of a handful of publicly traded companies, sent one private corporation into bankruptcy and rocked the bonds of several others, and now the litigation appears to be nearing a crescendo, Josh Nathan-Kazis writes in this week's edition of Barron's. Despite the few discrete settlements that have been reached - included one that resulted in privately held Purdue Pharma filing for bankruptcy - a final resolution for the majority of the companies remains far off, the author noted. Among the names that could potentially face additional legal liabilities steaming from opioid lawsuits are Johnson & Johnson (JNJ), Teva Pharmaceutical (TEVA), Endo International (ENDP), Mallinckrodt (MNK), Abbott Laboratories (ABT), Amneal Pharmaceuticals (AMRX), Mylan (MYL), McKesson (MCK), Cardinal Health (CAH), AmerisourceBergen (ABC), Walgreens Boots Alliance (WAB), and CVS Health (CVS). 4 In the biggest opening of all time for specialty distributor Focus Features, "Downton Abbey" won weekend box office with a better than expected $31M from 3,079 locations. Overseas, the movie earned $30.8M from 32 markets for an early global haul of $61.8M. The pic received an A CinemaScore and 85% on Rotten Tomatoes. 5. RealReal (REAL), Softbank, Chipotle (CMG), McDonald's (MCD), Yum! Brands (YUM), Wendy's (WEN), Restaurant Brands (QSR), Comcast (CMCSA), Delta Air Lines (DAL), Diamondback Energy (FANG), Encompass Health (EHC), Facebook (FB), Microsoft (MSFT), Procter & Gamble (PG), Coca-Cola (KO), PepsiCo (PEP), Colgate-Palmolive (CL), Kimberly Clark (KMB) and Kellogg (K) saw positive mentions in this week's edition of Barron's.

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

DB

Deutsche Bank

$7.99

-0.08 (-0.99%)

BNPQY

BNP Paribas

$0.00

(0.00%)

JNJ

Johnson & Johnson

$131.73

1.75 (1.35%)

TEVA

Teva

$7.44

-0.08 (-1.06%)

ENDP

Endo

$3.48

0.115 (3.42%)

MNK

Mallinckrodt

$2.46

0.01 (0.41%)

ABT

Abbott

$83.56

0.35 (0.42%)

AMRX

Amneal Pharmaceuticals

$3.34

0.21 (6.71%)

MYL

Mylan

$21.01

0.03 (0.14%)

MCK

McKesson

$146.83

1.06 (0.73%)

CAH

Cardinal Health

$47.89

-0.14 (-0.29%)

ABC

AmerisourceBergen

$85.13

0.475 (0.56%)

WAB

Wabtec

$74.01

0.26 (0.35%)

CVS

CVS Health

$64.28

0.65 (1.02%)

REAL

RealReal

$17.00

0.21 (1.25%)

CMG

Chipotle

$835.17

3.67 (0.44%)

MCD

McDonald's

$209.44

-1.12 (-0.53%)

YUM

Yum! Brands

$112.31

-1.83 (-1.60%)

WEN

Wendy's

$20.77

0.22 (1.07%)

QSR

Restaurant Brands

$72.64

-1.24 (-1.68%)

CMCSA

Comcast

$46.36

-0.32 (-0.69%)

CMCSK

Comcast

$0.00

(0.00%)

DAL

Delta Air Lines

$58.63

-0.05 (-0.09%)

FANG

Diamondback Energy

$96.90

-0.45 (-0.46%)

EHC

Encompass Health

$64.41

-0.01 (-0.02%)

FB

Facebook

$189.88

-0.27 (-0.14%)

MSFT

Microsoft

$139.34

-1.74 (-1.23%)

PG

Procter & Gamble

$122.22

0.37 (0.30%)

KO

Coca-Cola

$53.90

-0.62 (-1.14%)

PEP

PepsiCo

$134.49

-0.98 (-0.72%)

CL

Colgate-Palmolive

$70.97

0.01 (0.01%)

KMB

Kimberly-Clark

$135.13

0.9 (0.67%)

K

Kellogg

$63.79

0.07 (0.11%)

  • 23

    Sep

  • 23

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 24

    Sep

  • 25

    Sep

  • 25

    Sep

  • 26

    Sep

  • 01

    Oct

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 15

    Oct

  • 16

    Oct

  • 18

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 01

    Nov

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

SFTBY SoftBank
$0.00

(0.00%)

02/28/19
BTIG
02/28/19
NO CHANGE
Target $60
BTIG
Buy
SoftBank price target raised to $60 from $50 at BTIG
BTIG analyst Walter Piecyk raised his price target on SoftBank (SFTBY) to $60 and kept his Buy rating, citing his "better understanding" of the previously acquired ARM Holdings business which warrants a higher multiple. The analyst also sees a major catalyst coming in the "imminent decision" around Sprint (S) / T-Mobile (TMUS) deal, which could amount to additional $14 price target impact on Softbank shares.
07/08/19
WBLR
07/08/19
NO CHANGE
WBLR
Outperform
AeroVironment can take 'material' share in $15B market, says William Blair
AeroVironment (AVAV) can take "material" market share from the $15B per year satellite manufacturing industry as a supplier to Softbank (SFTBY), William Blair analyst Louie DiPalma tells investors in a research note after meeting with the head of Softbank's Advanced Technology Division, Ryuji Wakikawa. The analyst points out that Softbank in January 2018 formed a joint venture with AeroVironment called HAPSMobile to develop high-altitude, solar-powered drones for the purpose of providing next-generation Internet of Things connectivity. HAPSMobile now represents nearly 20% of AeroVironment's sales, DiPalma says. He affirms an Outperform rating on AeroVironment shares.
SFTBF SoftBank
$0.00

(0.00%)

12/12/18
RBCM
12/12/18
NO CHANGE
Target $230
RBCM
Outperform
Nvidia price target lowered to $230 from $260 at RBC Capital
RBC Capital analyst Mitch Steves lowered his price target on Nvidia (NVDA) to $230 after yesterday's report that Softbank (SFTBF) is exploring the sale of its stake in the company early next year. The analyst believes that in the near-term, the speculation is a negative since Softbank has "solid information on overall Data Center trends". Steves maintains his Outperform rating however, stating that a number of long-only investment managers have not participated in the run-up of the stock price. The analyst adds that Nvidia's long-term investment story around "AI/VR/AR/Autonomous" driving remains intact.
02/28/19
BTIG
02/28/19
NO CHANGE
Target $60
BTIG
Buy
SoftBank price target raised to $60 from $50 at BTIG
BTIG analyst Walter Piecyk raised his price target on SoftBank (SFTBY) to $60 and kept his Buy rating, citing his "better understanding" of the previously acquired ARM Holdings business which warrants a higher multiple. The analyst also sees a major catalyst coming in the "imminent decision" around Sprint (S) / T-Mobile (TMUS) deal, which could amount to additional $14 price target impact on Softbank shares.
WE We Company
$0.00

(0.00%)

09/10/19
09/10/19
NO CHANGE

We Company IPO is 'full speed ahead,' CNBC reports
The initial public offering of We Company is moving "full speed ahead" despite reports of the valuation reductions, CNBC's David Faber reports, citing sources close to the situation.
DB Deutsche Bank
$7.99

-0.08 (-0.99%)

07/08/19
RBCM
07/08/19
NO CHANGE
RBCM
Underperform
Deutsche Bank business review 'more radical than expected', says RBC Capital
RBC Capital analyst Anke Reingen raised her price target on Deutsche Bank to EUR8 from EUR7.50, saying its transformation plan announced over the weekend is "more radical than expected" and could support its shares over the short term. The analyst maintained her Underperform rating however, noting that the bank's execution will be key, while also pointing to the company's pushed out projections for improvement in profitability.
07/08/19
BOFA
07/08/19
NO CHANGE
BOFA
Underperform
BofA keeps Underperform rating on Deutsche Bank, says capital still an issue
After Deutsche Bank released its outline of its new plan to improve profitability, BofA Merrill Lynch analyst Andrew Stimpson said the cost ambitions are greater than he expected, but he believes capital will continue to be an issue as the bank decided to not raise equity. Also, preliminary Q2 underlying results missed consensus, noted Stimpson, who keeps an Underperform rating on Deutsche Bank shares with many details of the company's plan still outstanding.
07/12/19
UBSW
07/12/19
UPGRADE
UBSW
Neutral
Deutsche Bank upgraded to Neutral from Sell at UBS
UBS upgraded Deutsche Bank to Neutral from Sell following the recent selloff in the shares.
07/12/19
07/12/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Buy from Neutral at Goldman Sachs with analyst Judy Hong saying the valuations in the tobacco sector are trading at a 10-year trough in spite of the "more accommodating" macro backdrop for Consumer Staples that includes a late cycle and lower yields. 2. Focus Financial (FOCS) upgraded to Outperform from Market Perform at Keefe Bruyette. 3. Deutsche Bank (DB) upgraded to Neutral from Sell at UBS. 4. Morgan Stanley (MS) upgraded to Buy from Neutral at Citi. 5. Snap (SNAP) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying the company's new Android app, the launch of Snap Games, and new viral lenses should accelerator user growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BNPQY BNP Paribas
$0.00

(0.00%)

04/03/19
BOFA
04/03/19
INITIATION
BOFA
Neutral
BNP Paribas reinstated with a Neutral at BofA/Merrill
BofA/Merrill reinstated coverage of BNP Paribas with an Neutral rating. The firm has a cautious view on French banks saying the need to build up capital will take many years and that 2020 targets are "uninspiring."
09/09/19
SOCG
09/09/19
DOWNGRADE
SOCG
Sell
BNP Paribas downgraded to Sell from Hold at Societe Generale
Societe Generale analyst Geoffrey Dawes downgraded BNP Paribas to Sell from Hold.
09/13/19
MSCO
09/13/19
DOWNGRADE
MSCO
Equal Weight
BNP Paribas downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Bruce Hamilton downgraded BNP Paribas to Equal Weight from Overweight with a price target of 50 euros, down from 57.60 euros. The analyst sees declining profitability and a tight capital path.
JNJ Johnson & Johnson
$131.73

1.75 (1.35%)

08/27/19
LEHM
08/27/19
NO CHANGE
Target $140
LEHM
Equal Weight
Barclays views J&J ruling as favorable, keeps Equal Weight rating
The $572M ruling last night against Johnson & Johnson is far less than the $17.2B Oklahoma was asking for and less than what the market was bracing for, Barclays analyst Kristen Stewart tells investors in a research note. As such, the analyst views the ruling favorably and believes it could ultimately be lower following J&J's appeal. However, litigation has and is likely to remain an overhang for the stock, says the analyst. She keeps an Equal Weight rating on shares of Johnson & Johnson with a $140 price target.
08/27/19
WELS
08/27/19
NO CHANGE
WELS
Outperform
Opioid ruling should assuage Johnson & Johnson investor fears, says Wells Fargo
Wells Fargo analyst Larry Biegelsen thinks decision in Oklahoma is a net positive for Johnson & Johnson in that the amount the judge ordered the company to pay - $572M - was well below the amount the plaintiffs requested - $17.5B. Further, the analyst notes that the amount was for abatement of the entire opioid crisis in Oklahoma, not just Johnson & Johnson's share of it, which seems like something the company should be able to overturn or reduce on appeal. Although J&J plans to appeal the ruling, Biegelsen expects the company to eventually settle this and other opioid cases. Big picture, he estimates Johnson & Johnson will eventually settle the opioid litigation for between $5B-10B payable over several years which admittedly is a rough guess at this time. He has an Outperform rating on the shares.
08/27/19
JPMS
08/27/19
NO CHANGE
JPMS
Neutral
Johnson & Johnson verdict well below feared worst case, says JPMorgan
The $572M verdict against Johnson & Johnson in Oklahoma came in well below the feared worst case, as investor expectations for the verdict increased over the past few weeks to over $1B, JPMorgan analyst Chris Schott tells investors in a research note. Further, the analyst believes the company has "strong legal grounding" to potentially overturn and/or reduce the verdict. Nonetheless, Schott still sees a more balanced risk/reward near-term for J&J shares and remain on the sidelines with a Neutral rating.
08/27/19
FBCO
08/27/19
NO CHANGE
Target $156
FBCO
Outperform
Opioid ruling reduces uncertainty, helps J&J move higher, says Credit Suisse
Credit Suisse analyst Matt Miksic notes that Johnson & Johnson appeared to react favorably to Oklahoma opioid ruling, due in part, to the $572M penalty being substantially lower than the $17B sought by State prosecutors. The analyst believes the decision helped reduce the range of uncertainty related to the potential opioid-related liability Johnson & Johnson could face, specifically in Oklahoma, if not across the U.S. more broadly. Miksic reiterates an Outperform rating and $156 target on the shares.
TEVA Teva
$7.44

-0.08 (-1.06%)

08/07/19
EVER
08/07/19
DOWNGRADE
EVER
In Line
Evercore ISI sees 'lots more uncertainty' at Teva, downgrades to In Line
As previously reported, Evercore ISI analyst Umer Raffat downgraded Teva to In Line from Outperform in light of new disclosures today that he believes "have introduced lots more uncertainty." The company's cash flows "have been a HUGE issue," its debt maturities "haven't been managed properly," the opioid litigation situation is getting more unclear and its CFO is departing, said Raffat, who removed his price target Teva shares.
08/08/19
RAJA
08/08/19
NO CHANGE
Target $15
RAJA
Outperform
Teva price target lowered to $15 from $22 at Raymond James
Raymond James analyst Elliot Wilbur lowered his price target for Teva Pharmaceutical to $15 from $22 but maintained an Outperform rating following the company's quarterly results. While Teva's shares continue to struggle to locate a bottom, Wilbur tells investors in a research note that "the song remains the same on fundamentals hummed to the tune of stability." A return to at least modest growth in 2020 and beyond appears highly likely at this juncture with U.S. generics on the rebound, he adds. Wilbur says he continues to see upside scenarios in Teva shares over the next 12-18 months given bottom in U.S. generics, further signs the Copaxone hole will be by new brand launches and further potential quantification around opioid liabilities emerges.
08/08/19
RHCO
08/08/19
NO CHANGE
Target $7
RHCO
Hold
Teva price target lowered to $7 from $10 at SunTrust
SunTrust analyst Gregg Gilbert lowered his price target on Teva to $7 and kept his Hold rating in spite of its Q2 earnings beat. The analyst says the quarter was decent with "continued stability" seen in North America generics, but he is concerned about the perception of the departure of Teva's CEO. Gilbert also points to Teva becoming the first company in his coverage to reserve a sum for potential opioid settlements.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Neutral
Teva assumed with a Neutral at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Teva Pharmaceuticals with a Neutral rating and a $6-$8 fair value range, saying that "expectations for global generics appear right sized." Flanders believes the company should be able to meaningfully address its debt over the next 3-5 years, but noted it will also have to contend with opioid litigation and price collusion litigation that cost $4B-$8B and $1B, respectively. He added that Teva will need to address both its branded pipeline and biosimilars in the medium-term future.
ENDP Endo
$3.48

0.115 (3.42%)

07/15/19
MSCO
07/15/19
DOWNGRADE
Target $3
MSCO
Underweight
Endo downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Endo International to Underweight from Equal Weight and cut his price target for the shares to $3 from $8.
07/15/19
MSCO
07/15/19
DOWNGRADE
MSCO
Underweight
Endo, Teva downgraded to Underweight on underappreciated risks at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Endo International (ENDP) and Teva Pharmaceutical (TEVA), both to Underweight from Equal Weight, cut his price target on Endo shares to $3 from $8 and lowered his price target for Teva shares to $6 from $16. In the wake of Amneal's (AMRX) recent 28% EBITDA guidance cut, Risinger noted that Amneal faces company-specific challenges but also said he is concern about potentially worsening U.S. competitive pricing pressure. He is worried that Endo and Teva both face "underappreciated" risks from buying group pressure being worse than expected, increasing competition among generic manufacturers and the fact that opioid litigation is "just getting started" with thousands of lawsuits having been filed. Risinger also cut his earnings estimates for Mylan (MYL) lowered his price target on its shares to $22 from $32, though he maintains an Overweight rating on that generic drugmaker, citing low valuation and the potential for corporate action. Risinger additionally lowered his price target on Amneal shares to $4 from $12.
07/15/19
07/15/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Teva (TEVA) and Endo (ENDP) downgraded to Underweight from Equal Weight at Morgan Stanley. 2. Marriott (MAR) downgraded to Neutral from Buy at Longbow with analyst Alton Stump citing valuation. 3. General Electric (GE) downgraded to Neutral from Buy at UBS with analyst Damian Karas saying that a "notable" decline in interest rates and the continued weakness in the power market combine toward a "more balanced" upside with downside. 4. WageWorks (WAGE) downgraded to Hold from Buy at Stifel with analyst David Grossman saying he does not envision a competing takeover offer for the company. 5. L Brands (LB) downgraded to Neutral from Buy at Citi with analyst Paul Lejuez saying his former view on the stock was based on the belief that a Victoria's Secret turnaround could be successful if the brand adopted a more inclusive approach. However, with management slow to implement meaningful change, and "cultural norms shifting away from them," it may be "too little too late" for a meaningful turnaround at Victoria's Secret. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Neutral
Endo assumed with a Neutral at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Endo International with a Neutral rating and a $2-$4 fair value range. The analyst noted that the upcoming opioid litigation, which Endo has significant exposure to, will be hard to call, but he estimates $3B-$4B in opioid liability paid out over ten years, and believes the risks are already reflected in the stock.
MNK Mallinckrodt
$2.46

0.01 (0.41%)

09/05/19
09/05/19
DOWNGRADE
Target $3

Market Perform
Mallinckrodt cut to Market Perform at BMO Capital on opioid restructuring report
As previously reported, BMO Capital analyst Gary Nachman downgraded Mallinckrodt to Market Perform and slashed his price target to $3 from $19 after yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. The analyst contends that an already challenging situation has "taken a turn for the worse", stating that he previously believed that the company would be able to navigate through these issues. Nachman adds that with the mounting pressures related to the litigation, the possibility of bankruptcy for Mallinckrodt can no longer be ruled out.
09/05/19
09/05/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. BHP Group (BHP) downgraded to Underperform from Neutral at Exane BNP Paribas. 2. Mallinckrodt (MNK) downgraded to Market Perform from Outperform at BMO Capital analyst Gary Nachman citing yesterday's Bloomberg reports that the company hired restructuring firms to help manage through its opioid litigation. 3. Yirendai (YRD) downgraded to Underperform from Neutral at Macquarie with analyst Dexter Hsu saying the company not only reported "disappointing" Q2 results, but also closed the merger with CreditEase on unfavorable terms. 4. Green Dot (GDOT) downgraded to Hold from Buy at Jefferies with analyst John Hecht saying the company's organic revenue growth has been slowing and it is trying to establish share in a new customer target market with well-resourced competitors. 5. Royal Dutch Shell (RDS.A, RDS.B) downgraded to Market Perform from Outperform at Cowen with analyst Jason Gabelman saying the downgrade reflects its peer leading exposure to international gas prices which are forecasted lower through 2020 and as a result could limit its free cash flow growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/09/19
STFL
09/09/19
NO CHANGE
Target $8
STFL
Hold
Mallinckrodt price target lowered to $8 from $20 at Stifel
Stifel analyst Annabel Samimy lowered her price target for Mallinckrodt shares to $8 from $20 after she reduced her expected growth of Acthar for 2019 and beyond and factored in more concrete potential litigation cash-calls. She models a $300M potential settlement with CMS related to the Acthar AMP-pricing reversion and has included a $900M potential liability for opioid-litigation payments, calling those her "best, reasonable estimates at this point" but acknowledging there still remains considerable uncertainty around both issues. Mallinckrodt's settlement of Track 1 of the Ohio multi-district litigations is "only a small step in the sprawling opioid litigation," but the settlement buys the company much-needed time to address New York state litigation or a global settlement, said Samimy, who keeps a Hold rating on Mallinckrodt shares.
09/10/19
STFL
09/10/19
NO CHANGE
STFL
Mallinckrodt's sale of BioVectra helps alleviate cash pressure, says Stifel
Stifel analyst Annabel Samimy maintained a Hold rating and $8 price target on Mallinckrodt, but noted that Mallinckrodt announced the sale of its CDMO organization, BioVectra, to HIG Capital for a potential $250M, which the analyst believes is "a positive step to manage and bolster cash and maintain capital allocation priorities." Samimy added that, with the departure of Specialty Generics President Matthew Harbaugh, the company's suspension of the spin-off appears indefinite.
ABT Abbott
$83.56

0.35 (0.42%)

04/29/19
PIPR
04/29/19
NO CHANGE
Target $165
PIPR
Overweight
Piper reiterates Overweight on DexCom after 'robust' teen survey results
There were 8,042 responses to Piper Jaffray's teen survey in February and March, of which 1,707 have diabetes or a member of their household does, analyst JP McKim tells investors in a research note. The survey implies underlying continuous glucose monitoring market growth of close to 58%, says the analyst. Abbott (ABT) reported 70% Libre growth in Q1 and DexCom (DXCM) reports May 1, McKim points out. He expects "continued strong growth" from DexCom following the "robust" survey results and reiterates an Overweight rating on the shares with a $165 price target.
07/18/19
BMOC
07/18/19
NO CHANGE
Target $94
BMOC
Outperform
Abbott price target raised to $94 from $87 at BMO Capital
BMO Capital analyst Joanne Wuensch raised her price target on Abbott to $94 and kept her Outperform rating after its Q2 earnings beat and a raise in FY19 guidance, saying the company is among a "handful" of medtech names that deliver above-market revenue and double-digit earnings growth along with operating leverage. The analyst notes that following its AbbVie spinoff and acquisition of St. Jude Medical and Alere, Abbott's growth drivers of Alinity, Libre and MitraClip are "humming along" - a trend she expects to continue.
07/18/19
COWN
07/18/19
NO CHANGE
Target $95
COWN
Outperform
Abbott price target raised to $95 from $86 at Cowen
Cowen analyst Joshua Jennings raised his price target on Abbott to $95 from $86 following Q2 earnings. The analyst said the quarter's highlight was the organic sales growth of 7.5% which was above its target of 7.0%, reflecting continued strength for Libre, MitraClip, and Alinity. He noted management raised it guidance for organic sales growth and earnings and he believes the company can continue to post above consensus results in the second half of the year. Jennings reiterated his Outperform rating on Abbott shares.
07/18/19
JEFF
07/18/19
NO CHANGE
Target $98
JEFF
Buy
Abbott price target raised to $98 from $80 at Jefferies
Jefferies analyst Raj Denhoy raised his price target for Abbott Laboratories to $98 from $80 saying the company's growth story is "still going strong" following its Q2 results. The quarter is more proof that the pharma exit and medtech "double-down" was right move, Denhoy tells investors in a research note. Despite Abbott's "strong" current momentum, each product cycle is still in early innings, adds the analyst. He keeps a Buy rating on the shares.
AMRX Amneal Pharmaceuticals
$3.34

0.21 (6.71%)

07/30/19
PIPR
07/30/19
NO CHANGE
PIPR
Neutral
Piper says Alkermes scores 'back-to-back wins' with settlement, Biogen data
Piper Jaffray analyst Danielle Brill said Alkermes (ALKS) has scored "back-to-back wins" with its announcement yesterday that it settled the ongoing Vivitrol patent dispute with Amneal (AMRX) and the news this morning that BIIB098 showed a statistically significant improvement on GI tolerability versus Tecfidera in a head-to-head Phase 3 trial. She still questions how meaningful the improvement in GI tolerability actually is, but thinks the drug may become a priority for partner Biogen (BIIB), Brill tells investors. The analyst, who views the news of the last two days as net positive for Alkermes, maintains her concerns about long-term value creation and the company's "dry pipeline," she said. Brill keeps a Neutral rating on Alkermes shares.
08/06/19
RHCO
08/06/19
NO CHANGE
Target $5
RHCO
Buy
Amneal Pharmaceuticals price target lowered to $5 from $9 at SunTrust
SunTrust analyst Gregg Gilbert lowered his price target on Amneal Pharmaceuticals to $5 after its Q2 earnings miss and announced departures of "industry veterans" Chairman and CEO, saying his updated model now anticipates lower revenue and gross margins for the company's generics business. The analyst also maintains a Buy rating on Amneal Pharmaceuticals but recommends that investors take a wait-and-see approach before considering a long position.
09/11/19
GUGG
09/11/19
INITIATION
Target $2.5
GUGG
Sell
Amneal Pharmaceuticals initiated with a Sell at Guggenheim
Guggenheim analyst Dana Flanders started Amneal Pharmaceuticals with a Sell rating and $2.50 price target.
09/11/19
GUGG
09/11/19
INITIATION
GUGG
Sell
Amneal Pharmaceuticals assumed with a Sell at Guggenheim
Guggenheim analyst Dana Flanders assumed coverage of Amneal Pharmaceuticals with a Sell rating and a $2.50 price target. Flanders believes the current consensus is too optimistic about the company's forward growth prospects, and noted that his estimates are 10% below consensus.
MYL Mylan
$21.01

0.03 (0.14%)

07/30/19
MSCO
07/30/19
DOWNGRADE
Target $40
MSCO
Equal Weight
Morgan Stanley downgrades Pfizer, says Upjohn deal 'exposes' weak earnings power
Morgan Stanley analyst David Risinger downgraded Pfizer (PFE) to Equal Weight from Overweight and lowered his price target for the shares to $40 from $48. The stock closed yesterday down 4% to $41.45. Pfizer's planned exit of Upjohn "exposes" the lower than expected earnings for both the remaining business and Upjohn, Risinger tells investors in a research note. The analyst says his thesis that Pfizer would outperform due to improving prospects was "invalidated" by a re-set of earnings on both sides of the business. The company's 2020 disclosures revealed earnings power that is much weaker than we realized, says Risinger. As such, he reduced his 2020 adjusted earnings per share estimate for Pfizer by 15% to $2.56 from $3.02.
07/30/19
MSCO
07/30/19
NO CHANGE
Target $25
MSCO
Overweight
Mylan price target raised to $25 from $22 at Morgan Stanley
Morgan Stanley analyst David Risinger raised his price target on Mylan (MYL) shares from $22 to $25 following the company's deal to combine with Pfizer's (PFE) Upjohn unit. He expects multiple to expand given the positives he sees from the deal, including greater global scale and strength, lower leverage, an attractive dividend yield and improved corporate governance, Risinger stated. He estimates the NewCo to have an enterprise value of $54B and net debt of about $24B, which yields $30B in equity value, which he used to arrive at a share price estimate of $25.
09/04/19
COWN
09/04/19
NO CHANGE
Target $48
COWN
Outperform
Pfizer shares remain attractively valued, says Cowen
Cowen analyst Steve Scalia updated his Pfizer (PFE) model following Q2 results, the closing of the Glaxo (GSK) Consumer joint venture, and the announcement that its Upjohn business would be divested and combined with Mylan (MYL). The analyst lowered his estimates to reflect what is left at the company and despite his revision feels the shares remain attractively valued. Scalia reiterated his Outperform rating and $48 price target on Pfizer shares.
09/19/19
JPMS
09/19/19
NO CHANGE
Target $37
JPMS
Neutral
Pfizer price target lowered to $37 from $46 at JPMorgan
JPMorgan analyst Chris Schott lowered his price target for Pfizer (PFE) to $37 from $46 and keeps a Neutral rating on the shares. While the Mylan (MYL)/Upjohn transaction creates a smaller, innovation-driven biopharma business and increases the company's near-term growth prospects, Pfizer's multiple is ahead of itself with the remaining company trading near the top end of the major pharma valuation range, Schott tells investors in a research note. He points out that Pfizer is facing "another major patent cycle" post 2025.
MCK McKesson
$146.83

1.06 (0.73%)

07/22/19
FBCO
07/22/19
INITIATION
Target $143
FBCO
Neutral
McKesson reinstated with a Neutral at Credit Suisse
Credit Suisse analyst Erin Wilson Wright reinstated coverage of McKesson with a Neutral rating and $143 price target. The analyst says her incrementally positive bias stems from evidence of stabilizing trends across the U.S. pharmaceutical supply chain, where she sees relief from easing generic deflation as well as enhanced visibility across branded price inflation and rebate paradigms. That said, with its shares up 26% from a low in March, Wright sees limited room for upside, acknowledging drug pricing scrutiny remains an overhang into an election cycle, along with other potential headwinds such as opioid litigation.
08/05/19
WOLF
08/05/19
DOWNGRADE
WOLF
Peer Perform
McKesson downgraded to Peer Perform from Outperform at Wolfe Research
Wolfe Research downgraded McKesson to Peer Perform from Outperform citing share outperformance.
08/06/19
CLVD
08/06/19
NO CHANGE
CLVD
Neutral
Cardinal Health recently lost 2 major accounts, says Cleveland Research
Cleveland Research analyst Rob Eich reports that his contacts indicate that Cardinal Health (CAH)recently lost two large specialty pharmacy contracts, including one to AmerisourceBergen (ABC) and one to McKesson (MCK). He estimates these contracts, which both should transition in about the first 6 months of FY20, represent $2B-$3B in annualized sales and are likely to be a drag on revenue growth of about 125-175 basis points, Eich told investors in a pre-open research note. He keeps a Neutral rating on Cardinal Health shares.
09/11/19
DBAB
09/11/19
INITIATION
Target $155
DBAB
Hold
McKesson initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated McKesson with a Hold rating and a price target of $155 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, its European business and domestic opioid litigation.
CAH Cardinal Health
$47.89

-0.14 (-0.29%)

08/27/19
ARGS
08/27/19
DOWNGRADE
ARGS
Hold
Cardinal Health downgraded to Hold from Buy at Argus
08/27/19
08/27/19
DOWNGRADE

Hold
Cardinal Health downgraded to Hold from Buy at Argus
As previously reported, Argus analyst David Toung downgraded Cardinal Health to Hold, saying the margins of its Pharmaceutical Distribution segment remain under pressure entering FY20 after a 23bps contraction in FY19. The analyst cites the management's expectations of margins in this segment declining by high single to low double digits this year because of the pricing of renewal contracts and higher legal expenses related to opioid litigation. Toung adds that he is also concerned with Cardinal Health's sluggish growth in the Medical segment because of the higher operating expenses coming from the integration of Cordis acquisition.
08/27/19
08/27/19
DOWNGRADE

Fly Intel: Top analyst downgrades
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Cardinal Health (CAH) downgraded to Hold from Buy at Argus with analyst David Toung saying the margins of its Pharmaceutical Distribution segment remain under pressure entering FY20 after a 23bps contraction in FY19. 2. Red Robin (RRGB) downgraded to Underperform from Neutral at BofA/Merrill with analyst Gregory Francfort saying he believes the company's earnings growth will "materially miss" consensus expectations in 2020. 3. T-Mobile (TMUS) downgraded to Perform from Outperform at Oppenheimer. 4. Ultrapar (UGP) downgraded to Hold from Buy at Santander. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
DBAB
09/11/19
INITIATION
Target $50
DBAB
Hold
Cardinal Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated Cardinal Health with a Hold rating and a price target of $50 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, recent large customer repricings, and opioid litigation.
ABC AmerisourceBergen
$85.13

0.475 (0.56%)

05/14/19
RAJA
05/14/19
NO CHANGE
RAJA
Walgreens could target Amerisource, LabCorp if it seeks M&A, says Raymond James
Raymond James analyst John Ransom said he thinks that "the temptation" for Walgreens (WBA) to do "something" in terms of M&A will grow over time and the "something" it may consider could include either acquiring AmerisourceBergen (ABC) or LabCorp (LH). His analysis points to LabCorp being a less complicated, "but much less accretive," deal, said Ransom. Given Walgreens' existing ownership of about a 26% stake in AmerisourceBergen, he estimates 16% accretion from buying the company for $95 per share in cash if he assumes $500M of synergies and $2B of opioid fines financed with debt, the analyst tells investors. Though such a deal would make financial sense, he does not think investors would "be overly excited about the strategic upside," Ransom tells investors. While he argues that LabCorp "offers more strategic upside," such a hypothetical deal also has less financial benefit, according to Ransom.
07/11/19
RAJA
07/11/19
NO CHANGE
RAJA
Death of drug rebate rule a win for PBMs and distributors, says Raymond James
After multiple media outlets, including Politico, reported that the Trump Administration has decided to withdraw the drug rebate rule, Raymond James analyst Chris Meekins called the news "a win" for pharmacy benefit managers and drug distributors and "a slight negative" for the pharmaceutical makers. The cost of the proposal to the government was ultimately too high with little guarantee that list prices would go down, said Meekins. However, President Trump hinted something "major" on drug pricing was coming over the next week during his kidney care speech and the analyst thinks the President is planning to move forward with an executive order on pricing. Publicly traded pharmaceutical distributors include McKesson (MCK), Cardinal Health (CAH), Amerisource (ABC) and Patterson (PDCO). Owners of pharmacy benefit managers include CVS Health (CVS), UnitedHealth (UNH), Anthem (ANTM) and Cigna (CI). Publicly traded large cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
09/11/19
DBAB
09/11/19
INITIATION
Target $91
DBAB
Hold
AmerisourceBergen initiated with a Hold at Deutsche Bank
Deutsche Bank analyst George Hill initiated AmerisourceBergen with a Hold rating and a price target of $91 as part of a broader research note on Healthcare Technology & Services. The analyst is positive on the "structural position" of the wholesalers in the drug supply chain, but warns that the company is faced with issues related to brand drug pricing, generic drug pricing, volumes shifting towards lower-margin customers and opioid litigation.
WAB Wabtec
$74.01

0.26 (0.35%)

08/07/19
GSCO
08/07/19
UPGRADE
Target $89
GSCO
Buy
Wabtec upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Jerry Revich upgraded Wabtec to Buy from Neutral and raised his price target for the shares to $89 from $84. Slowing freight traffic and cost overruns on transit projects are now well understood with the stock down 34% over the past 12 months, Revich tells investors in a research note. Meanwhile, locomotive capital stock has been "significantly reduced" cycle to date, and Wabtec's high recurring revenue base is attractive on a relative basis amid deteriorating end market demand for other industrial end markets, says the analyst. Further, he believes the GE Transportation integration is off to a strong start.
09/10/19
MSCO
09/10/19
INITIATION
Target $73
MSCO
Equal Weight
Wabtec initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Courtney Yakavonis started Wabtec with an Equal Weight rating and $73 price target. While the analyst sees upside to the company's 2019 earnings, she believes Precision Scheduled Railroading has introduced uncertainty into long-term locomotive demand. Further, long-term accretion from the GE Transportation merger may be capped by lower locomotive orders, Yakavonis tells investors in a research note.
09/16/19
KEYB
09/16/19
UPGRADE
Target $90
KEYB
Overweight
Wabtec upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Steve Barger upgraded Wabtec to Overweight from Sector Weight with a $90 price target.
09/16/19
09/16/19
UPGRADE
Target $90

Overweight
Wabtec upgraded to Overweight at KeyBancG
As previously reported, KeyBanc analyst Steve Barger upgraded Wabtec (WAB) to Overweight from Sector Weight with a $90 price target. The analyst cited expectations that Wabtec can generate stable-to-growing revenue from its global footprint and sizable backlog, margin expansion from integrating the GE (GE) locomotive business, and better performance in Transit. In coming quarters, Barger thinks the combination of one-time acquisition-related costs rolling off, synergy realization, and eventual stabilization/recovery in Wabtec's cyclical businesses will result in improving EPS and cash flow.
CVS CVS Health
$64.28

0.65 (1.02%)

08/08/19
SBSH
08/08/19
NO CHANGE
Target $72
SBSH
Buy
CVS Health price target raised to $72 from $68 at Citi
Citi analyst Ralph Giacobbe raised his price target for CVS Health to $72 from $68 saying the company's Q2 results showed "encouraging trends," particularly within retail and pharmacy benefit manager segments. He believes the stock "should have done better on the print" and reiterates a Buy rating on CVS Health.
08/09/19
MSCO
08/09/19
NO CHANGE
Target $74
MSCO
Overweight
CVS's Q2 gives window into possible power of the enterprise, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser said CVS Health's Q2 results and conference call "provided a window to what the power of the enterprise could materialize into," citing improved retail comps, share gains and the company's Medicare Advantage strategies. The analyst, who thinks the company's opportunity to capture share in Medicare Advantage organically by cross-selling is underestimated by the market, keeps an Overweight rating and $74 price target on CVS shares.
08/27/19
COWN
08/27/19
NO CHANGE
Target $76
COWN
Outperform
CVS Health price target raised to $76 from $69 at Cowen
Cowen analyst Charles Ryhee raised his price target on CVS Health to $76 from $69 to reflect revised 2019 guidance. The analyst believes the 2019 guidance looks conservative and with faster synergy realization and improved 2020 selling season, the company's 2020 guidance looks achievable. Ryhee reiterated his Outperform rating on CVS Health shares.
09/11/19
DBAB
09/11/19
INITIATION
Target $91
DBAB
Buy
CVS Health initiated with a Buy at Deutsche Bank
Deutsche Bank analyst George Hill initiated CVS Health with a Buy rating and a Top Pick designation along with a price target of $91 as part of a broader research note on Healthcare Technology & Services. The analyst contends that the company is "well positioned to deliver on a vertical integration care delivery strategy", capturing market share and generating positive earnings surprises. Hill also sees the valuation of CVS shares as "highly compelling".
REAL RealReal
$17.00

0.21 (1.25%)

08/14/19
KEYB
08/14/19
NO CHANGE
Target $31
KEYB
Overweight
RealReal Q2 performance points to strength of product mix, says KeyBanc
Commenting on RealReal's quarterly results, KeyBanc analyst Edward Yruma notes that the company's 40% year over year Gross Merchandise Volume growth points to the "strong demand" for value-priced luxury goods. There was some modest impact to AOV from a promotional environment, but the analyst thinks performance during the Q2 points to the strength of its product mix. Yruma reiterates an Overweight rating and $31 price target on the shares.
09/03/19
WELS
09/03/19
INITIATION
Target $20
WELS
Outperform
RealReal initiated with an Outperform at Wells Fargo
Wells Fargo analyst Ike Boruchow started RealReal with an Outperform rating and $20 price target. As the number one player in the "rapidly growing" used luxury goods category, the company is "extremely" well positioned to capitalize on the meaningful total addressable market, Boruchow tells investors in a research note. Further, he believes RealReal's business model is key to driving greater supply of secondhand luxury merchandise in the marketplace. The analyst feels comfortable assuming 25%-30% sales growth for RealReal for the foreseeable future, and also believes the company should see meaningful scale.
09/03/19
09/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Wayfair (W) initiated with a Buy at Goldman Sachs. 2. Square (SQ) initiated with an Underweight at Atlantic Equities. 3. InMode (INMD) initiated with an Outperform at Baird, an Overweight at Barclays, and a Buy at Canaccord and UBS. 4. Sanofi (SNY) initiated with an Outperform at Bernstein. 5. RealReal (REAL) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/11/19
COWN
09/11/19
NO CHANGE
Target $32
COWN
Outperform
RealReal remains on attractive path to profitability, says Cowen
Cowen analyst Oliver Chen said RealReal remains on an attractive path to profitability while noting it remains a controversial stock with a high percentage short interest. The analyst believes its business has recovered form the promotional environment in Q2, pricing can stay competitive, and the returning customer retention rate is high at mid-90%. Chen reiterated his Outperform rating and $32 price target on RealReal shares.
CMG Chipotle
$835.17

3.67 (0.44%)

08/30/19
GSCO
08/30/19
NO CHANGE
Target $1100
GSCO
Conviction Buy
Chipotle 'got it right' with Queso Blanco, bullish Goldman analyst says
Chipotle Mexican Grill's menu innovation is showing positive early reads while digital metrics suggest continued strong traffic growth this quarter on the digital ecosystem, Goldman Sachs analyst Katherine Fogertey tells investors in a research note. The analyst's 12-month price target of $1,000 points to 18% upside potential and she keeps a Conviction Buy rating on Chipotle. She see signs that Chipotle "has got it right" with Queso Blanco. The feedback from the testing sites has been overwhelmingly positive, with sell outs and restocks being a repeated issue, Fogertey notes after speaking to store employees and customers. The analyst believes the new Queso could drive comps and remains confident in her bullish view on Chipotle.
09/09/19
WEDB
09/09/19
UPGRADE
WEDB
Outperform
Chipotle upgraded to Outperform from Neutral at Wedbush
09/09/19
09/09/19
UPGRADE
Target $980

Outperform
Chipotle upgraded to Outperform at Wedbush
As previously reported, Wedbush analyst Nick Setyan upgradec Chipotle to Outperform from Neutral and raised his price target on the shares to $980 from $780. As the industry transitions towards a larger mix of digital transactions, the analyst believes Chipotle is in a leading position to establish a digital moat. Setyan not only continues to see near-term momentum as management executes towards this transition, he believes Chipotle is poised to sustain outsized same-store sales and EPS growth in the medium- to long-term in an industry where a dearth of growth is likely to command an increasing premium.
09/09/19
09/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) upgraded to Buy from Hold at Deutsche Bank with analyst Carlo Santarelli saying Bearish Macau sentiment has created an opportunistic entry point for medium to longer term investors. 2. Genesco (GCO) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz citing the company's Q2 beat and guidance increase. 3. Entergy (ETR) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Tenure saying unlike some of its large premium valuation peers, Entergy has potential for both high rate base growth and improving earned returns on equity. 4. SAIC (SAIC) upgraded to Outperform from Market Perform at Cowen with analyst Cai Von Rumohr saying the "sharp selloff" in shares has resulted in favorable risk/reward and raised its price target to $102.00. 5. Chipotle (CMG) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying as the industry transitions towards a larger mix of digital transactions, the analyst believes Chipotle is in a leading position to establish a digital moat. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MCD McDonald's
$209.44

-1.12 (-0.53%)

08/14/19
LBOW
08/14/19
NO CHANGE
LBOW
Neutral
McDonald's checks point to continued 'robust' U.S. comp growth, says Longbow
Longbow analyst Alton Stump said his conversations with McDonald's franchisees in the U.S. lead him to believe same-store sales are up 5%-5.5% to date in Q3. The analyst, who noted that consensus is for McDonald's U.S. comps to grow 5.2% in the current quarter, keeps a Neutral rating on McDonald's shares.
08/20/19
BMOC
08/20/19
UPGRADE
Target $36
BMOC
Outperform
Pilgrim's Pride upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Kenneth Zaslow upgraded Pilgrim's Pride (PPC) to Outperform and raised his price target to $36 from $31, citing the management's implementation of a "successful execution" of its chicken strategy. The analyst also points to the improvement in "underlying chicken fundamentals" around the shortage of U.S. beef production, record high levels in China hog prices, and a "more normal" promotional activity that includes increased features with McDonald's (MCD) upcoming chicken promotion - its first in over a year.
08/23/19
SPHN
08/23/19
NO CHANGE
SPHN
McDonald's 'notably missing' from 'chicken sandwich wars,' says Stephens
Stephens analyst Will Slabaugh said he believes the combination of Popeye's new chicken sandwich and its "well-executed social media blitz" have helped drive same-store sales growth for the brand into the high-single to low-double digits since the product launch. While Popeye's only represents 12% of parent Restaurant Brands' (QSR) store base, he still thinks the "chicken sandwich wars," which have made the news, are important for the story as he believes the brand will become a larger part of the company, and Restaurant Brands licensee Carrols Restaurant (TAST), over time. Slabaugh also said he views this as a missed opportunity at McDonald's (MCD), where a quality chicken sandwich product could help guest counts. The analyst keeps Overweight ratings on shares of both franchisor Restaurant Brands and franchisee Carrols.
08/29/19
CLVD
08/29/19
NO CHANGE
CLVD
Neutral
McDonald's Q3 comps tracking better than consensus, says Cleveland Research
Research analyst Steven Gojak says McDonald's Q3 comps are tracking better than the 5.2% consensus estimate on strong check growth and throughput improvements. The analyst maintains his 6% comp estimate and thinks the company's momentum can continue in Q4. However, Gojak believes McDonald's 2020 outlook "is a bit cloudier at this point" and keeps a Neutral rating on the shares.
YUM Yum! Brands
$112.31

-1.83 (-1.60%)

08/02/19
BMOC
08/02/19
NO CHANGE
Target $112
BMOC
Market Perform
Yum! Brands price target raised to $112 from $98 at BMO Capital
BMO Capital analyst Andrew Strelzik raised his price target on Yum! Brands to $112 after its Q2 earnings beat and stronger comps across all brands that offset weaker operating margins. The analyst also notes that the company's two-year comp stack is now at its highest level in over 5 years, with added potential upside coming from the management's efforts to refocus Pizza Hut units on delivery. Strelzik keeps his Market Perform rating on Yum! Brands due to valuation.
08/02/19
BTIG
08/02/19
NO CHANGE
Target $130
BTIG
Buy
Yum! Brands price target raised to $130 from $114 at BTIG
BTIG analyst Peter Saleh raised his price target on Yum! Brands (YUM) to $130 and kept his Buy rating after its Q2 earnings beat. The analyst says he remains confident in the company's global sales and business momentum along with the "robust" consumer environment and "steadily unfolding" international unit development. Saleh adds that Yum! Brands is benefiting from its expanding partnership with Grubhub (GRUB).
08/12/19
MKMP
08/12/19
INITIATION
Target $125
MKMP
Neutral
Yum! Brands initiated with a Neutral at MKM Partners
MKM Partners analyst Brett Levy started Yum! Brands with a Neutral rating and $125 price target.
08/13/19
08/13/19
INITIATION
Target $125

Neutral
Yum! Brands initiated with a Neutral at MKM Partners
As previously reported, MKM Partners analyst Brett Levy started Yum! Brands with a Neutral rating and $125 price target. The analyst says the company's "highly franchised model" has produced a "solid cash flow story" with double digit earnings growth. Levy further cites Yum! Brands driving "operational progress" at Taco Bell and KFC brands, anticipating Pizza Hut to also overcome its challenges, but believes that the company's accelerating unit growth and "solid" fundamentals are priced into the stock in the near term.
WEN Wendy's
$20.77

0.22 (1.07%)

09/10/19
BMOC
09/10/19
NO CHANGE
Target $21
BMOC
Outperform
Wendy's breakfast plan increases operational risk, says BMO Capital
BMO Capital analyst Andrew Strelzik kept his Outperform rating and $21 price target on Wendy's after the company announced plans to launch a national breakfast offering in 2020 and lowered its FY19 guidance to reflect the $20M upfront franchisee investment. The analyst notes that the announcement represents a growth opportunity, even though it introduces a layer of operational and financial risk that he had previously not assumed. Strelzik intends to review his forecasts after Wendy's offers mode detail on its plans at the upcoming October Investor Day.
09/10/19
GUGG
09/10/19
DOWNGRADE
GUGG
Neutral
Guggenheim downgrades Wendy's to Neutral on risky breakfast expansion
As previously reported, Guggenheim analyst Matthew DiFrisco downgraded Wendy's to Neutral from Buy following the company's announcement of plans to enter breakfast with a nationwide offering. The analyst, who noted that management reduced its 2019 outlook to account for a $20M upfront investment relating to launching breakfast across the U.S. system, views the day-part expansion as a sign of slowing near-term momentum in the lunch and dinner business. He also notes that Wendy's previous attempts to establish a breakfast business in 1985, 2006 and 2010 were unsuccessful and pressured franchise margins, calling the new attempt "a potentially risky way to add topline growth."
09/10/19
09/10/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wendy's (WEN) downgraded to Neutral from Buy at Guggenheim and BTIG. 2. The Stars Group (TSG) downgraded to Underweight from Equal Weight at Barclays. 3. Whiting Petroleum (WLL) and Jagged Peak Energy (JAG) downgraded to Neutral from Buy at BofA/Merrill. 4. Dollar General (DG) downgraded to Market Perform from Outperform at Bernstein with analyst Brandon Fletcher saying he believes its future story is well understood, and the upside is probably priced into the stock already. 5. Wells Fargo (WFC) downgraded to Neutral from Buy at UBS with analyst Saul Martinez citing his reduced estimates for earnings and lower net interest income along with the continued uncertainty and low visibility around the progress in the management's efficiency improvements. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
LBOW
09/13/19
NO CHANGE
Target $25
LBOW
Buy
Wendy's franchisees 'surprisingly positive' on breakfast plans, says Longbow
Longbow analyst Alton Stump said his conversations with U.S. Wendy's franchisees leads him to believe that the sharp negative reaction by investors to the company's breakfast announcement was unwarranted. His contacts expressed "an admittedly surprisingly positive view" of plans to re-launch breakfast nationwide in 2020, pointing to a simpler menu, lower food cost as a percentage of sales, expectations for only a modestly higher labor spend and a nationwide rollout as key reasons for their optimism, said Stump. He also noted that his checks make him believe domestic franchised same-store sales were up 3-3.5% in Q3 to date, which is tracking ahead of his and consensus estimates. Stump has a Buy rating and $25 price target on Wendy's shares.
QSR Restaurant Brands
$72.64

-1.24 (-1.68%)

09/05/19
PIPR
09/05/19
NO CHANGE
Target $90
PIPR
Overweight
Restaurant Brands price target raised to $90 from $80 at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan raised her price target for Restaurant Brands to $90 from $80 saying the company continues to perform fundamentally and benefit from franchise and portfolio value in relation to the restaurant cycle. Investors should continue buying the shares for both growth through organic development as well as potential acquisitions, Regan tells investors in a research note. She reiterates an Overweight rating on Restaurant Brands.
09/17/19
ARGS
09/17/19
INITIATION
ARGS
Buy
Restaurant Brands initiated with a Buy at Argus
09/17/19
ARGS
09/17/19
INITIATION
Target $90
ARGS
Buy
Restaurant Brands initiated with a Buy at Argus
Argus analyst John Staszak initiated Restaurant Brands with a Buy rating and a price target of $90. The analyst contends that the company's acquired brands Tim Horton's and Popeye's Louisiana Kitchen can grow in international markets through master franchise joint venture agreements similarly to the growth seen at Burger King. Staszak further contends that the management of Restaurant Brands will have the ability to open new stores and drive higher comps with initiatives around deliveries, daypart expansion, and plant-based products.
09/17/19
09/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Match Group (MTCH) initiated with a Buy at Citi. 2. Restaurant Brands (QSR) initiated with a Buy at Argus. 3. Orchard Therapeutics (ORTX) initiated with a Buy at Guggenheim. 4. Axonics (AXNX) initiated with an Outperform at SVB Leerink. 5. Cellular Biomedicine (CBMG) initiated with a Buy at BTIG. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CMCSA Comcast
$46.36

-0.32 (-0.69%)

09/19/19
GUGG
09/19/19
NO CHANGE
GUGG
Buy
Guggenheim sees broadband gains continuing, ups targets for Altice USA, Charter
Guggenheim analyst Mike McCormack said he expects video adds to remain under pressure at cable companies amid continued programming pressure and customer defections. However, seasonality should help broadband trends in Q3, said the analyst, who expects both Altice USA (ATUS) and Charter (CHTR) to see accelerating gains year-over-year and for Comcast (CMCSA) to report slightly weaker, but still strong, broadband additions. He keeps Buy ratings on all three cable companies. McCormack has an unchanged $52 price target on Comcast, raised his Altice target to $33 from $32 and increased his Charter target to $488 from $440.
09/19/19
DADA
09/19/19
NO CHANGE
Target $185
DADA
Buy
Roku value proposition 'significantly different' from Comcast, says DA Davidson
DA Davidson analyst Tom Forte keeps his Buy rating and $185 price target on Roku (ROKU), defending the company after the 13.7% decline in its stock price yesterday amid competitive concerns about Comcast (CMCSA) offering a free set-top box for OTT video consumption. The analyst contends that "lowest cost provider" and "Comcast" rarely go hand in hand as customers will likely pay "hefty fees" for connectivity. Forte recommends that investors purchase Roku shares to take advantage of yesterday's pullback, also maintaining that the secular OTT shift remains in its "early innings".
09/19/19
RSBL
09/19/19
NO CHANGE
Target $134
RSBL
Buy
Roku pullback an 'overreaction' to Comcast's free streaming box, says Rosenblatt
Rosenblatt analyst Mark Zgutowicz said yesterday's weakness in Roku (ROKU) shares was related to news that Comcast (CMSCA) will give its Xfinity Flex streaming box to its broadband only customers for free. However, he thinks the potential impact to Roku looks modest. He thinks Roku has a significant customer acquisition advantage via smart TV sell through, noting that Roku TV sales have represented an estimated 1 of 3 smart TVs sold this year. Zgutowicz maintains a Buy rating and $134 price target on Roku shares, which are down another 1% to $128.26 in pre-market trading.
09/20/19
PIVT
09/20/19
INITIATION
Target $60
PIVT
Sell
Pivotal starts 'dramatically overvalued' Roku with Sell rating, $60 target
Pivotal Research analyst Jeffrey Wlodarczak initiated coverage of Roku (ROKU) with a Sell rating and $60 price target. The streaming service closed yesterday up 3% to $133.76. The emergence of "dramatically" more competition will likely drive the cost of over-the-top devices to zero and put "material" pressure on advertising revenue splits, Wlodarczak tells investors in a research note partially titled "Is ROKU BROKU?" Comcast's (CMCSA) recent moves with its free Xfinity Flex product will likely be copied by other distributors, adds the analyst. He believes Comcast's move to free will materially reduce Roku's potential outsized subscriber growth and average revenue per user opportunities, or the reasons for the stock's "premium" valuation. Roku management deserves credit for the asset they have created, but "everyone has realized the living room is too important and the big boys with massive leverage" are likely to make the company's growth much more difficult, argues Wlodarczak. The analyst believes that despite the recent selloff, shares of Roku are still "dramatically overvalued."
CMCSK Comcast
$0.00

(0.00%)

02/11/19
KEYB
02/11/19
NO CHANGE
Target $216
KEYB
Overweight
Workday price target raised to $216 from $179 at KeyBanc
KeyBanc analyst Brent Bracelin raised his price target for Workday (WDAY) to $216 from $179 on improving cloud growth prospects. The analyst notes that analysis of Key First Look Data: Jobs has exposed an unannounced F50 HCM win at UPS (UPS) that began hiring for the global HR transformation team in January. The data also exposed unannounced F100 HCM wins at Comcast (CMCSA; CMCSK), CapitalOne (COF), and Centene (CNC), although job dates suggest these deals may have closed in the October quarter. The January data also exposed a new cloud financials win at Adecco (AHEXY), Bracelin adds. The analyst reiterates an Overweight rating on Workday's shares.
07/29/19
FBCO
07/29/19
NO CHANGE
FBCO
Credit Suisse sees virtually no impact for AT&T, Verizon from Dish near-term
Following the Justice Department's settlement with T-Mobile (TMUS) and Sprint (S), Credit Suisse analyst Douglas Mitchelson notes that for Altice USA (ATUS), the settlement requires mobile virtual network operator contracts to be extended through at least 7 years post closing, which he views as a "significant positive" for Altice. For cable broadly, Dish (DISH) would represent an "intriguing option" for entry into the wireless business longer-term if CEO decided to sell the company, he contends. The analyst would expect that Comcast (CMCSA) and Charter (CHTR) would wait until the point where wireless pricing and valuations are thought to have bottomed. For AT&T (T) and Verizon (VZ), Mitchelson sees virtually no impact from Dish the next few years as the company will be just focused on scaling marketing of its T-Mobile MVNO while building its wireless network. Longer-term, while Dish might be in a position to deflate wireless pricing, AT&T and Verizon should still have superior coverage, network density, backhaul, scale, and quality of service, he adds.
08/14/19
MACQ
08/14/19
DOWNGRADE
Target $31
MACQ
Neutral
Viacom downgraded to Neutral from Outperform at Macquarie
Macquarie analyst Tim Nollen downgraded Viacom (VIAB) to Neutral from Outperform and keeps a Neutral rating on CBS (CBS) shares after the two companies announced a merger deal with no premium for Viacom following "3 years of on again/off again merger discussions amidst wrenching change in the industry." While he believes the deal's strategic positives outweigh the risks, Nollen said integration might not be easy and that ViacomCBS will still be "small-ish" compared with competitors Comcast (CMCSA) and Disney (DIS). He lowered his price target on Viacom shares to $31 from $37 and cut his price target on CBS shares to $53 from $55.
DAL Delta Air Lines
$58.63

-0.05 (-0.09%)

07/29/19
MACQ
07/29/19
DOWNGRADE
MACQ
Neutral
Macquarie warns about pricing pressure among airlines from Southwest competition
Macquarie analyst Susan Donofrio downgraded American Airlines (AAL), Spirit Airlines (SAVE), Hawaiian Holdings (HA), and Alaska Air (ALK) to Neutral from Outperform as part of a broader industry note, saying the competitive environment for these airlines should become "choppy" in the fall of 2019 and in 2020 as Southwest (LUV) attempts to win back market share. The analyst believes that the latter's sizable domestic scope should lead to "unit revenue softness" within the overall pricing structure, through she maintains an Outperform rating on United Airlines (UAL), Delta (DAL) and Allegiant (ALGT) given their ongoing revenue initiatives and minimal overlap with Southwest.
09/06/19
BREN
09/06/19
INITIATION
Target $72
BREN
Buy
Delta Air Lines initiated with a Buy at Berenberg
Berenberg started Delta Air Lines with a Buy rating and $72 price target.
09/06/19
BREN
09/06/19
INITIATION
BREN
Berenberg says big 4 airlines can generate cash, prefers American and Delta
As previously reported, Berenberg analyst Adrian Yanoshik initiated coverage of the four largest U.S. airlines, starting American Airlines (AAL) with a Buy rating and $35 price target, Delta Air Lines (DAL) with a Buy rating and $72 price target, United Continental (UAL) with a Hold rating and $95 price target and Southwest Airlines (LUV) with a Hold rating and $57 price target. Amid market worries over both capacity growth and demand weakness, his work suggests that U.S. airlines can generate free cash flow in "all scenarios but a 9/11-scale shock," Yanoshik tells investors. He thinks airline sector valuations reflect fears, but overlook broadly stable, albeit two-tiered, returns. He would buy American with valuation at multi-year lows as he estimates that American will narrow its margin gap to peers and thinks it debt burden is misunderstood. He would also buy Delta, which Yanoshik calls "arguably the highest-quality airline."
09/16/19
WBLR
09/16/19
NO CHANGE
WBLR
Outperform
Gogo shares rallying on Delta Wi-Fi plans, could hit $15, says William Blair
Gogo (GOGO) shares on Friday increased for the 12th consecutive trading session, William Blair analyst Louie DiPalma tells investors in a research note titled "They Say Mentioning a No-Hitter in the Middle of a No-Hitter Is Bad Luck... Stay Tuned." The analyst believes the primary driver behind the recent stock movement is anticipation for Delta Air Lines' (DAL) planned rollout of free Wi-Fi, and the potential positive impact on Gogo's financials. Delta's rollout of free Wi-Fi will require Delta to break and amend its existing contract with Gogo that lasts until 2027, says DiPalma. The analyst points out that Delta's Twitter account tweeted on September 9: "Delta expanded its partnership with Gogo inflight (our Wi-Fi provider) for the launch of free Wi-Fi. In preparation, testing of 55 markets began in May. We are committed to delivering a product that will add continued value to your travel experience. Stay tuned!" DiPalma thinks it is possible that Delta CEO Ed Bastian provides more details at the September 18 SKIFT Global Forum in New York City. The analyst sees Gogo shares in 2021 appreciating to a range of $10 to $15, which corresponds to a free cash flow yield of 6.6% to 9.8%. He keeps an Outperform rating on the name.
FANG Diamondback Energy
$96.90

-0.45 (-0.46%)

09/06/19
TDSI
09/06/19
DOWNGRADE
TDSI
Buy
Diamondback Energy downgraded to Buy from Action List Buy at TD Securities
TD Securities analyst Juan Jarrah downgraded Diamondback Energy to Buy from Action List Buy citing "significant" shares outperformance versus peers and maintained a $155 price target.
09/16/19
JPMS
09/16/19
NO CHANGE
Target $152
JPMS
Overweight
Diamondback valuation discount to peers unwarranted, says JPMorgan
JPMorgan analyst Michael Glick says his analysis suggests Diamondback Energy "paces the group on nearly every important measure," including capital efficiency, margins and free cash flow. However, the stock still trades at a discount to peers and the group on multiple metrics, which is unjustified, Glick tells investors in a research note. He believes Diamondback should trade at a premium relative to the group and the Permian as a whole. The analyst boosted his price target for the shares to $152 from $149 and keeps an Overweight rating on the name.
09/17/19
STFL
09/17/19
NO CHANGE
STFL
Buy
Viper Energy acquisition of Permian acreage attractive, says Stifel
Stifel analyst Timothy Howard said Viper Energy Partners' agreement to acquire royalty acres in the Permian basin from Santa Elena Minerals was "attractive," demonstrates Viper's unique strategy and suggests positive sentiment on the partnership's valuation. He views the deal favorably and maintains a Buy rating on Viper Energy shares.
09/19/19
JPMS
09/19/19
INITIATION
Target $34
JPMS
Overweight
Viper Energy initiated with an Overweight at JPMorgan
JPMorgan analyst Michael Glick started Viper Energy (VNOM) with an Overweight rating and $34 price target. The company's "symbiotic relationship" with Diamondback Energy (FANG) brings "significant" visibility, Glick tells investors in a research note.
EHC Encompass Health
$64.41

-0.01 (-0.02%)

09/06/19
BOFA
09/06/19
UPGRADE
BOFA
Buy
Encompass Health upgraded to Buy from Neutral at BofA/Merrill
09/06/19
BOFA
09/06/19
UPGRADE
Target $73
BOFA
Buy
Encompass Health upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Kevin Fischbeck upgraded Encompass Health to Buy from Neutral with a $73 price target. While 2020 will be a reset year, Encompass has already taken down expectations to the point where the risks appear priced in, Fischbeck tells investors in a research note. He believes the company is well positioned to adjust to home health reimbursement changes and points out it has little exposure to "Medicare for All" headline risk.
09/16/19
DBAB
09/16/19
INITIATION
DBAB
Hold
Encompass Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Justin Bowers startedEncompass Health with a Hold rating and $70 price target.
09/16/19
DBAB
09/16/19
INITIATION
Target $70
DBAB
Hold
Encompass Health initiated with a Hold at Deutsche Bank
Deutsche Bank analyst Justin Bowers started Encompass Health with a Hold rating and a $70 price target as part of his broader research note into the Post-Acute sector in the Healthcare Facilities industry, saying the fundamentals of the public home health pure-plays are attractive despite payment reform beginning in 2020. The analyst is also positive on the company's "high quality management team" and its "market leading franchises", but sees its 2020 headwind in the home health and hospice segment as too "brisk" to overcome, stating that its high mix of therapy will pressure the segment next year.
FB Facebook
$189.88

-0.27 (-0.14%)

09/05/19
RHCO
09/05/19
NO CHANGE
RHCO
Buy
Match selloff on Facebook Dating launch a buying opportunity, says SunTrust
SunTrust analyst Youssef Squali views the selloff today in shares of Match Group (MTCH) on Facebook's (FB) launch of Facebook Dating as a buying opportunity. Match's portfolio approach of brands, the "under-penetration" of the category in most markets served, and its leadership position in most markets should allow it to continue to show "healthy growth" with relatively limited impact from Facebook's dating product, Squali tells investors in a research note. Further, he believes "some negative reputational overhang" from the last couple years may prevent mass adoption of Facebook's service. In addition, Facebook's dating feature could potentially attract an older demographic than seen on Match's fastest growing brands such as Tinder and Hinge, says Squali. The analyst maintains a Buy rating on Match Group, whose stock is down 6% to $80.31 in midday trading.
09/10/19
OPCO
09/10/19
NO CHANGE
OPCO
Perform
Facebook dating survey suggests potential risk for Match Group, says Oppenheimer
Oppenheimer analyst Jason Helfstein surveyed 440 singles to gauge early response to Facebook (FB) Dating, and results highlighted that 40% of respondents were aware of the Facebook Dating product within 48 hours of initial launch in the U.S. Conversion of "aware" users was 15%, and the analyst expects awareness to grow significantly, yielding double digit penetration if the conversion ratio holds. Survey results point to a younger than expected user base, putting Facebook Dating in direct competition with Tinder, he contends. While historical download-data of initial Facebook Dating points to minimal Tinder impact, Helfstein notes that survey results make a compelling argument for near-term headwinds to Match Group (MTCH) shares, coupled with adverse short-term effects from a potential spin of. The analyst has a Perform rating on Match Group's shares.
09/10/19
GUGG
09/10/19
NO CHANGE
GUGG
Guggenheim sees no evidence of Facebook Dating hurting Match's Tinder
Facebook (FB) Dating is now live in 20 countries and Guggenheim analyst Jake Fuller, in a research note earlier to investors, said he cannot find an example where Match Group's Tinder "took a hit." Further, the analyst points out that Facebook Dating has been live in Canada since November 2018 and that his firm's data shows Tinder daily active users up 45% and downloads up 51% since the launch. Strong" Tinder downloads yield the potential for upside to consensus estimates when Match reports Q3 results, the analyst writes. Despite the launch of Facebook Dating in the U.S., the analyst says his perspective on Match is improving. Nonetheless, Fuller kept a Neutral rating on shares of Match Group, whose stock is down 10c to $77.86 in morning trading.
09/17/19
SUSQ
09/17/19
UPGRADE
Target $18
SUSQ
Neutral
Susquehanna upgrades Snap to Neutral after positive advertising checks
Susquehanna analyst Shyam Patil upgraded Snap (SNAP) to Neutral from Negative and boosted his price target for the shares to $18 from $12. The stock closed Monday down 24c to $15.76. The analyst's recent advertising channel checks have suggested that Snap's "solid" growth has continued in Q3 with expectations for continued progress in Q4. The checks also show that Facebook's (FB) Instagram Stories "has lowered barriers" for SNAP Stories adoption, Patil tells investors in a research note. The analyst, who also expect Snap's net addition momentum to continue in the second half of 2019, says the stock's valuation is keeping him from getting even more constructive.
MSFT Microsoft
$139.34

-1.74 (-1.23%)

08/26/19
KEYB
08/26/19
NO CHANGE
Target $130
KEYB
Overweight
Xilinx price target lowered to $130 from $140 at KeyBanc
KeyBanc analyst John Vinh lowered his price target for Xilinx (XLNX) to $130 from $140 as he believes the launch of Microsoft's (MSFT) FPGA-as-a-Service has been postponed from Q4 to early next year due to the availability of a key software-related feature. The analyst expects Microsoft's FaaS to preview by the end of this year and go live early next year. While Vinh still believes Microsoft represents a significant opportunity longer term, he sees risk to 2020 estimates and to DCG expectations for 60% growth. Nonetheless, he reiterates an Overweight rating on Xilinx shares given long-term secular growth opportunities in 5G and Data Center.
08/29/19
WEDB
08/29/19
NO CHANGE
Target $160
WEDB
Outperform
Microsoft cloud momentum should continue, says Wedbush
Wedbush analyst Daniel Ives believes Microsoft (MSFT) remains in an enviable position heading into the rest of 2019 and 2020 on the heels of its cloud success and is firing on all cylinders around its Office 365 and Azure strategic vision based on his recent checks. So far in the September quarter, the analyst is seeing a clear acceleration of larger and more strategic enterprise cloud deals as he believes "Redmond is poised to win the lion's share of the next phase of cloud deployments vs. Amazon [AMZN] and Bezos." The shift to cloud is a major secular trend that is "significantly benefiting" Microsoft in the field and should continue its momentum heading into the next 12-18 months, he contends. Ives reiterates an Outperform rating and a $160 price target on Microsoft's shares.
09/12/19
MZHO
09/12/19
INITIATION
Target $26
MZHO
Neutral
Slack Technologies initiated with a Neutral at Mizuho
Mizuho analyst Gregg Moskowitz initiated Slack Technologies (WORK) with a Neutral rating and $26 price target. While he views the company's communications and collaboration platform as "best-in-class," Moskowitz said the competitive pressures it faces are "difficult to ignore." He thinks Microsoft's (MSFT) competing Teams service significantly reduces Slack's pricing power, the analyst said in his initiation note.
09/19/19
OPCO
09/19/19
NO CHANGE
OPCO
Outperform
Microsoft dividend, buyback should be welcomed by investors, says Oppenheimer
Oppenheimer analyst Timothy Horan expects Microsoft to trade up after management announced that it will increase its dividend 11%, a quarter earlier than historical trends and his expectations. In addition, management announced a massive $40B share buyback plan with no expiration, he adds. The analyst believes the move to increase the dividend and share buy-backs should be welcomed by investors. He reiterates an Outperform rating on the shares.
PG Procter & Gamble
$122.22

0.37 (0.30%)

07/31/19
WELS
07/31/19
NO CHANGE
Target $135
WELS
Outperform
Procter & Gamble price target raised to $135 from $125 at Wells Fargo
Wells Fargo analyst Bonnie Herzog raised her price target for Procter & Gamble to $135 from $125 as she believes "everything clicked into place" for the company in Q4, demonstrating that management's multi-year transformation is "clearly working." The analyst reiterates an Outperform rating on the shares.
08/12/19
MSCO
08/12/19
NO CHANGE
Target $129
MSCO
Overweight
Procter & Gamble EPS growth can outpace peers, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian reiterated his Overweight rating and $129 price target on Procter & Gamble (PG) following the company's Q4 report, which he said gave him greater confidence in his thesis that the company's market share gains and strong category pricing can continue to drive above-consensus topline growth. Coupled with P&G's outsized gross margin expansion, he expects higher EPS growth than peers, said Mohsenian, who also views the stock's valuation as "attractive."
09/11/19
MSCO
09/11/19
NO CHANGE
Target $144
MSCO
Underweight
Clorox valuation unwarranted given widening gap with peers, says Morgan Stanley
Morgan Stanley analyst Dara Mohsenian reiterates his Underweight rating on Clorox (CLX) shares despite the stock's recent underperfomance compared to peers such as Procter & Gamble (PG), Colgate-Palmolive (CL) and Church & Dwight (CHD) as he believes the company's decelerating topline growth, market share losses and lower gross margin expansion make the stock's current valuation compared to peers unwarranted. Though he is not yet revising his estimates, Mohsenian sees risk of downward earnings revisions if scanner trends continue to deteriorate, he tells investors. He maintains a $144 price target on Clorox shares.
09/18/19
MSCO
09/18/19
NO CHANGE
MSCO
EU Household & Personal Care sector downgraded to In-Line at Morgan Stanley
Morgan Stanley analyst Richard Taylor downgraded the European Household & Personal Care, or HPC, sector to In-Line from Attractive to reflect a fading pricing environment in the second half of 2019 and competitive pressures that he sees increasing. Procter & Gamble (PG), after nearly 10 years of losing share to the big players in Europe, is now growing fast and gaining share under new management, Taylor tells investors. His least preferred name in the group is Henkel (HENKY), on which he has an Underweight rating. Other European HPC companies include Unilever (UN, UL), Reckitt Benckiser (RBGLY) and L'Oreal (LRLCY).
KO Coca-Cola
$53.90

-0.62 (-1.14%)

07/29/19
ATLE
07/29/19
INITIATION
Target $62
ATLE
Overweight
Coca-Cola initiated with an Overweight at Atlantic Equities
Atlantic Equities started Coca-Cola with an Overweight rating and $62 price target.
07/29/19
ATLE
07/29/19
INITIATION
ATLE
Atlantic Equities starts Coca-Cola, PepsiCo with Overweight ratings
Atlantic Equities analyst Edward Lewis initiated coverage of Coca-Cola (KO) with an Overweight rating and $62 price target as well as PepsiCo (PEP) with an Overweight rating and $145 price target. Global consumer companies are returning to form in 2019 amid a positive global consumer backdrop, rational pricing and easing commodity cost inflation, Lewis tells investors in a research note. He believes both companies have leading market shares in attractive categories. Beverages and snacks are "attractive global markets delivering growth even as consumer preferences change," says Lewis. He sees Coca-Cola's and PepsiCo's "strong" global market shares bringing inherent advantages, such as acquiring new brands, entering new categories and reformulating their existing products.
07/29/19
07/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Domino's Pizza (DPZ) initiated with a Sell at Deutsche Bank and a Neutral at Goldman Sachs. 2. Oaktree Specialty Lending (OCSL) initiated with a Neutral at Janney Montgomery Scott. 3. Chipotle (CMG) initiated with a Conviction Buy at Goldman Sachs, while McDonald's (MCD), Starbucks (SBUX), and Shake Shack (SHAK) were initiated with a Buy, Restaurant Brands (QSR) and Yum! Brands (YUM) were initiated with a Neutral, and Wendy's (WEN) and Jack in the Box (JACK) were initiated with a Sell. 4. PepsiCo (PEP) and Coca-Cola (KO) initiated with an Overweight at Atlantic Equities. 5. Dell Technologies (DELL) initiated with an Outperform at Wells Fargo. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/19
MSCO
08/05/19
NO CHANGE
MSCO
Coca-Cola added to Fresh Money Buy List at Morgan Stanley
Morgan Stanley equity strategist Michael Wilson said he is shifting the firm's "Fresh Money Buy List" to be more defensive by adding Coca-Cola (KO) and removing LyondellBasell (LYB). At Coke, he expects an acceleration in EPS growth driven by stronger pricing power, volume growth and new products, said Wilson. In terms of the broader market, Wilson said new tariffs are not the only thing driving the market lower, pointing to full valuations, corporate profits turning lower and technical resistance as other factors ahead of "heavy Treasury issuance this month" that will add another headwind.
PEP PepsiCo
$134.49

-0.98 (-0.72%)

09/06/19
FBCO
09/06/19
NO CHANGE
Target $117
FBCO
Underperform
PepsiCo price target raised to $117 from $110 at Credit Suisse
Credit Suisse analyst Kaumil Gajrawala maintained an Underperform rating on PepsiCo and raised his price target to $117 from $110. In a research note to investors, the analyst says that a turnaround is likely to be driven by an improvement in its North American business, but believes "we are not yet at a sustainable inflection point that would allow PepsiCo to throttle back the spending" and deliver 8% EPS growth for 2020.
09/11/19
MSCO
09/11/19
NO CHANGE
Target $149
MSCO
Overweight
PepsiCo price target raised to $149 from $143 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian sees strong near-term revenue growth at PepsiCo being supported by an acceleration in U.S. scanner data and also believes the company has above peer topline growth potential over the longer term driven by its snacks business and international momentum. He also does not think Pepsi's high EPS visibility is fully priced into the stock given its discounted valuation compared to peers. Mohsenian reiterates an Overweight rating on PepsiCo and raised his price target on the shares to $149 from $143.
CL Colgate-Palmolive
$70.97

0.01 (0.01%)

04/29/19
JEFF
04/29/19
NO CHANGE
Target $73
JEFF
Hold
Colgate-Palmolive price target raised to $73 from $61 at Jefferies
Jefferies analyst Kevin Grundy raised his price target for Colgate-Palmolive to $73 from $61 following the company's "solid" Q1 results. While a recovery in China will take time, Colgate-Palmolive is "importantly seeing progress" across key markets, including the U.S. and Latin America, and the Colgate Total relaunch is progressing in-line with expectations, Grundy tells investors in a research note. He views the company's sales recovery as "encouraging," but thinks the stock's current valuation limits upside potential. As such, he keeps a Hold rating on Colgate-Palmolive.
04/29/19
04/29/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Target (TGT) upgraded to Overweight from Equal Weight at Barclays with analyst Matthew McClintock saying Target is taking market share from a "much weaker" retailer subset than other positive traffic retailers. 2. Sprouts Farmers Market (SFM) upgraded to Buy from Hold at Deutsche Bank. 3. American Airlines (AAL) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying American's lowering of its earnings guidance range last week was not unexpected given the recent rise in fuel prices and grounding of its MAX fleet. The analyst thinks the resetting of expectations by management establishes a "floor" for American's share price and provides the company a bit more "cushion" around its earnings targets. 4. Colgate-Palmolive (CL) upgraded to Neutral from Underweight at JPMorgan with analyst Andrea Teixeira saying the company's organic growth is "finally starting to show consistent improvement," despite mixed signals from most recent scanner data in the U.S. 5. Adobe (ADBE) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Keith Weiss saying his field work, meetings with management and analysis of segment contribution margins have boosted his confidence in Adobe's ability to sustain EPS growth of over 20%, even if he assumes decelerating Digital Media growth. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/11/19
ARGS
06/11/19
NO CHANGE
Target $82
ARGS
Buy
Colgate-Palmolive price target raised to $82 from $72 at Argus
Argus analyst Chris Graja raised his price target on Colgate-Palmolive to $82 and kept his Buy rating. The analyst cites the company's 2.4% dividend yield exceeding the 10-year Treasury note payout and expects that dividend to continue to increase. Graja also points to Colgate-Palmolive's accelerating organic sales growth in Q1 to 3% from 2% in Q4 driven by the management's more aggressive advertising initiatives, greater e-commerce product availability, and the company's high financial strength rating relative to his coverage universe.
KMB Kimberly-Clark
$135.13

0.9 (0.67%)

04/23/19
ARGS
04/23/19
UPGRADE
ARGS
Buy
Kimberly-Clark upgraded to Buy from Hold at Argus
04/23/19
04/23/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst James Faucette citing his view that the market has "not yet fully appreciated" the impact of the company's settlement with Apple (AAPL), which he thinks not only increases earnings substantially while also expanding the freedom with which Qualcomm can pursue new opportunities. 2. Kimberly-Clark (KMB) upgraded to Buy from Hold at Argus and to Outperform from Neutral at Macquarie. 3. Sanderson Farms (SAFM) upgraded to Neutral from Sell at Goldman Sachs with analyst Adam Samuelson saying African swine fever is upending the protein markets, Samuelson tells investors in a research note. 4. Visteon (VC) upgraded to Outperform from Neutral at Baird while Veoneer (VNE) was upgraded to Neutral from Underperform. 5. Sony (SNE) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/19
MSCO
06/18/19
NO CHANGE
Target $145
MSCO
Equal Weight
Morgan Stanley sees near-term upside in Kimberly-Clark from better input costs
The substantial decline in pulp prices recently, along with elevated pulp inventory levels, has materially changed Kimberly-Clark's input cost inflation outlook, according to Morgan Stanley analyst Dara Mohsenian. Given that the better input costs should drive near-term EPS upside, he is making a positive short-term trading call in the stock, predicting that the company will cut its input cost inflation guidance by $75M to $225-$325M and raise its FY19 EPS guidance to $6.60-6.80 from $6.50-6.70. Though Mohsenian raised his price target on Kimberly-Clark shares to $145 from $132, he keeps an Equal Weight rating on the stock on a longer-term view, as he still expects market share struggles and sees lower growth potential.
07/24/19
ATLE
07/24/19
UPGRADE
ATLE
Neutral
Kimberly-Clark upgraded to Neutral from Underweight at Atlantic Equities
Atlantic Equities analyst Edward Lewis upgraded Kimberly-Clark to Neutral from Underweight citing the company's "better performance" following its Q2 results.
K Kellogg
$63.79

0.07 (0.11%)

08/01/19
PIVT
08/01/19
NO CHANGE
Target $62
PIVT
Hold
Kellogg reported 'low-quality beat,' says Pivotal Research
Pivotal Research analyst Timothy Ramey said Kellogg reported a "low-quality beat" in Q2 and he doesn't see a reason "to get too bullish yet." While it was encouraging to see organic sales grow, the impacts of its divested businesses will be "quite fierce" though the second of quarter of 2020 and he does not see a path to growth until then, Ramey tells investors. He trimmed his estimates for both 2019 and 2020 and keeps a Hold rating on Kellogg shares with an unchanged price target of $62.
08/02/19
GUGG
08/02/19
NO CHANGE
Target $65
GUGG
Neutral
Kellogg price target raised to $65 from $55 at Guggenheim
Guggenheim analyst Laurent Grandet said he was encouraged by Kellogg's improved sales growth momentum in the quarter. He raised his EPS estimates for FY19-FY21 following the report and increased his price target on Kellogg shares to $65 from $55, but keeps a Neutral rating on the stock as he thinks most of the upside is now priced in given the stock's positive reaction.
09/06/19
GSCO
09/06/19
UPGRADE
Target $72
GSCO
Buy
Kellogg upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Jason English upgraded Kellogg to Buy and raised his price target to $72 from $58, saying the stock is the "most compelling value left in snacks" and has a visible path to accelerating its organic sales growth and growing its margins. The analyst cites the recent changes at the company sustaining its faster growth rate, including Kellogg divesting its cookie, fruit snack, pie crust and ice cream cone business as well as benefiting from rising enthusiasm from recent entrants in the "meat alternative" space.
09/06/19
09/06/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Kellogg (K) upgraded to Buy from Neutral at Goldman Sachs with analyst Jason English saying the stock is the "most compelling value left in snacks" and has a visible path to accelerating its organic sales growth and growing its margins. 2. DocuSign (DOCU) upgraded to Outperform from Neutral at Wedbush with analyst Daniel Ives saying the company returned to its "usual beat and raise story," proving last quarter was a "small blip on the radar." 3. Agco (AGCO) upgraded to Buy from Hold at Stifel with analyst Stanley Elliott saying after raveling with management, the analyst is "more encouraged" with the company's margin and market share initiatives. 4. Navistar (NAV) upgraded to Neutral from Sell at Goldman Sachs with analyst Jerry Revich saying he has a positive view of management's "newly cautious" view on 2020 truck demand and he believes freight rates appear to have stabilized. 5. Cheesecake Factory (CAKE) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jon Tower saying the recently announced acquisition of Fox Restaurant Concepts not only transforms the company's growth profile, but also diversifies its real estate footprint and leverages its existing infrastructure, human capital and purchasing scale. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

LOGI

Logitech

$40.72

0.66 (1.65%)

21:08
10/21/19
10/21
21:08
10/21/19
21:08
Earnings
Logitech backs FY20 revenue growth outlook in high single digits »

Backs FY20 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

LOGI

Logitech

$40.72

0.66 (1.65%)

21:06
10/21/19
10/21
21:06
10/21/19
21:06
Earnings
Logitech reports Q2 adjusted EPS 50c, consensus 50c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 04

    Nov

  • 05

    Nov

VG

Vonage

$10.35

-0.04 (-0.38%)

21:05
10/21/19
10/21
21:05
10/21/19
21:05
Hot Stocks
Vonage accelerates expansion into Asia Pacific »

Vonage is continuing its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PG

Procter & Gamble

$119.04

1.55 (1.32%)

, MCD

McDonald's

$209.85

1.365 (0.65%)

20:25
10/21/19
10/21
20:25
10/21/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$119.04

1.55 (1.32%)

MCD

McDonald's

$209.85

1.365 (0.65%)

UTX

United Technologies

$138.24

1.39 (1.02%)

NEE

NextEra Energy

$232.85

0.17 (0.07%)

LMT

Lockheed Martin

$373.16

0.54 (0.14%)

UPS

UPS

$118.56

1.23 (1.05%)

SHW

Sherwin-Williams

$551.04

-9.93 (-1.77%)

KMB

Kimberly-Clark

$139.31

2.01 (1.46%)

BIIB

Biogen

$223.57

3.52 (1.60%)

TRV

Travelers

$141.77

0.33 (0.23%)

PCAR

Paccar

$72.88

0.83 (1.15%)

FITB

Fifth Third

$28.04

0.71 (2.60%)

CNC

Centene

$45.83

-1.09 (-2.32%)

RF

Regions Financial

$16.08

0.305 (1.93%)

NUE

Nucor

$51.78

0.09 (0.17%)

HAS

Hasbro

$120.11

-1.78 (-1.46%)

TRU

TransUnion

$82.55

1.055 (1.29%)

DGX

Quest Diagnostics

$102.21

-0.465 (-0.45%)

IPG

Interpublic Group

$20.79

0.14 (0.68%)

HOG

Harley-Davidson

$37.14

0.555 (1.52%)

PII

Polaris Industries

$91.55

0.935 (1.03%)

SNV

Synovus

$36.30

1.005 (2.85%)

JBLU

JetBlue

$17.54

0.59 (3.48%)

GPK

Graphic Packaging

$14.86

0.205 (1.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 25

    Oct

  • 28

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 07

    Nov

  • 10

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

OISHY

Oil Search

$0.00

(0.00%)

20:01
10/21/19
10/21
20:01
10/21/19
20:01
Hot Stocks
Oil Search reports Q3 output 6.81MMBOE, down 1% qoq and down 10% yoy »

Cuts FY19 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EA

Electronic Arts

$95.81

0.63 (0.66%)

19:53
10/21/19
10/21
19:53
10/21/19
19:53
Downgrade
Electronic Arts rating change at Barclays »

Electronic Arts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 04

    Nov

  • 13

    Nov

TWTR

Twitter

$40.09

1.11 (2.85%)

, FB

Facebook

$189.82

3.865 (2.08%)

19:48
10/21/19
10/21
19:48
10/21/19
19:48
Hot Stocks
Twitter plans to update rules to address manipulated media on its platform »

The official Twitter…

TWTR

Twitter

$40.09

1.11 (2.85%)

FB

Facebook

$189.82

3.865 (2.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 30

    Oct

IRDM

Iridium

$24.23

-0.05 (-0.21%)

19:44
10/21/19
10/21
19:44
10/21/19
19:44
Hot Stocks
Iridium adds Intellian to Certus maritime portfolio »

Iridium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

, NVDA

Nvidia

$196.16

5.69 (2.99%)

19:29
10/21/19
10/21
19:29
10/21/19
19:29
Hot Stocks
Nvidia, Ericsson collaborate on virtualized 5G radio access technology »

NVIDIA (NVDA) and…

ERIC

Ericsson

$9.12

-0.075 (-0.82%)

NVDA

Nvidia

$196.16

5.69 (2.99%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 14

    Nov

  • 20

    Nov

NVDA

Nvidia

$196.16

5.69 (2.99%)

, MSFT

Microsoft

$138.43

1.09 (0.79%)

19:24
10/21/19
10/21
19:24
10/21/19
19:24
Hot Stocks
Nvidia announces technology collaboration with Microsoft »

NVIDIA (NVDA) with…

NVDA

Nvidia

$196.16

5.69 (2.99%)

MSFT

Microsoft

$138.43

1.09 (0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 26

    Oct

  • 27

    Oct

  • 29

    Oct

  • 06

    Nov

  • 14

    Nov

  • 20

    Nov

  • 21

    Nov

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

19:17
10/21/19
10/21
19:17
10/21/19
19:17
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

U.S. Bancorp will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

ADBE

Adobe

$266.84

1.42 (0.54%)

, AAPL

Apple

$240.49

4.2 (1.78%)

18:55
10/21/19
10/21
18:55
10/21/19
18:55
Periodicals
Adobe to roll out Illustrator app for iPad in 2020, Bloomberg reports »

Adobe (ADBE) has selected…

ADBE

Adobe

$266.84

1.42 (0.54%)

AAPL

Apple

$240.49

4.2 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 23

    Jan

NVDA

Nvidia

$196.16

5.69 (2.99%)

, IBM

IBM

$132.55

-1.55 (-1.16%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Hot Stocks
Nvidia, Red Hat to deliver 5G wireless infrastructure to telecom industry »

Nvidia (NVDA) and Red Hat…

NVDA

Nvidia

$196.16

5.69 (2.99%)

IBM

IBM

$132.55

-1.55 (-1.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 27

    Oct

  • 14

    Nov

  • 20

    Nov

SMBC

Southern Missouri Bancorp

$36.24

0.38 (1.06%)

18:43
10/21/19
10/21
18:43
10/21/19
18:43
Earnings
Southern Missouri Bancorp sees Q1 EPS 85c, consensus 78c »

The company announced Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 28

    Oct

  • 13

    Nov

CDNS

Cadence Design

$66.67

1.07 (1.63%)

, AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

18:36
10/21/19
10/21
18:36
10/21/19
18:36
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CDNS

Cadence Design

$66.67

1.07 (1.63%)

AMTD

TD Ameritrade

$37.65

0.86 (2.34%)

HLX

Helix Energy

$8.32

0.31 (3.87%)

ZION

Zions Bancorp

$45.68

0.96 (2.15%)

STMP

Stamps.com

$76.12

0.55 (0.73%)

UPS

UPS

$118.56

1.23 (1.05%)

FBP

First BanCorp

$10.24

-0.015 (-0.15%)

VRTX

Vertex

$183.73

7.49 (4.25%)

KDMN

Kadmon

$3.08

0.17 (5.84%)

TACO

Del Taco

$9.66

0.26 (2.77%)

HXL

Hexcel

$74.59

-1.62 (-2.13%)

SITC

Site Centers

$15.27

0.175 (1.16%)

ADC

Agree Realty

$77.01

1.365 (1.80%)

CE

Celanese

$121.37

-0.3 (-0.25%)

HHC

Howard Hughes

$128.38

2.41 (1.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 21

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 22

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 07

    Nov

  • 11

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 19

    Mar

  • 22

    Oct

USB

U.S. Bancorp

$56.19

1.125 (2.04%)

18:31
10/21/19
10/21
18:31
10/21/19
18:31
Periodicals
U.S. Bancorp to cut thousands of jobs from its branches, Bloomberg says »

The report cites an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

HLX

Helix Energy

$8.32

0.31 (3.87%)

18:16
10/21/19
10/21
18:16
10/21/19
18:16
Earnings
Helix Energy reports Q3 EPS 21c, consensus 16c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

  • 14

    Nov

CVX

Chevron

$116.66

1.87 (1.63%)

18:07
10/21/19
10/21
18:07
10/21/19
18:07
Periodicals
U.S. Treasury to let Chevron drill in Venezuela for 3 more months, Reuters says »

The U.S. Treasury…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

SFTBF

SoftBank

$0.00

(0.00%)

, WE

We Company

$0.00

(0.00%)

18:03
10/21/19
10/21
18:03
10/21/19
18:03
Periodicals
SoftBank's WeWork offer would lead to co-founder's exit, Reuters says »

SoftBank (SFTBF) offered…

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDEF

First Defiance Financial

$29.51

0.4 (1.37%)

17:59
10/21/19
10/21
17:59
10/21/19
17:59
Earnings
First Defiance Financial reports Q3 EPS 66c, consensus 60c »

Reports Q3 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 13

    Nov

UNFI

United Natural Foods

$6.91

0.35 (5.34%)

17:56
10/21/19
10/21
17:56
10/21/19
17:56
Recommendations
United Natural Foods analyst commentary  »

United Natural Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCPT

Four Corners Property Trust

$28.35

0.135 (0.48%)

17:45
10/21/19
10/21
17:45
10/21/19
17:45
Hot Stocks
Four Corners Property Trust acquires Maryland property for $2M »

Four Corners Property…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

RTN

Raytheon

$202.21

2.41 (1.21%)

17:39
10/21/19
10/21
17:39
10/21/19
17:39
Hot Stocks
Raytheon awarded $128.45M Air Force contract for mobile sensors maintenance »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GNTY

Guaranty Bancshares

$30.22

0.02 (0.07%)

17:38
10/21/19
10/21
17:38
10/21/19
17:38
Earnings
Guaranty Bancshares reports Q3 EPS 65c, consensus 56c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNC

Centene

$45.83

-1.09 (-2.32%)

, WCG

WellCare

$271.41

-3.13 (-1.14%)

17:32
10/21/19
10/21
17:32
10/21/19
17:32
Hot Stocks
Centene announces $500M share repurchase plan »

In a regulatory filing,…

CNC

Centene

$45.83

-1.09 (-2.32%)

WCG

WellCare

$271.41

-3.13 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.